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Abstract Glucagon-like Peptide-1 receptor agonists
(GLP1-ra) are a relatively new class of anti-hyperglycemic
drugs which may positively affect bone metabolism and
thereby decrease (osteoporotic) bone fracture risk. Data on
the effect of GLP1-ra on fracture risk are scarce and limited
to clinical trial data only. The aim of this study was to in-
vestigate, in a population-based cohort, the association be-
tween the use of GLP1-ra and bone fracture risk. We
conducted a population-based cohort study, with the use of
data from the Clinical Practice Research Datalink (CPRD)
database (2007–2012). The study population (N = 216,816)
consisted of all individuals with type 2 diabetes patients with
at least one prescription for a non-insulin anti-diabetic drug
and were over 18 years of age. Cox proportional hazards
models were used to estimate the hazard ratio of fracture in
GLP1-ra users versus never-GLP1-ra users. Time-dependent
adjustments were made for age, sex, lifestyle, comorbidity
and the use of other drugs. There was no decreased risk of
fracture with current use of GLP1-ra compared to never-
GLP1-ra use (adjusted HR 0.99, 95 % CI 0.82–1.19). Os-
teoporotic fracture risk was also not decreased by current
GLP1-ra use (adjusted HR 0.97; 95 % CI 0.72–1.32). In
addition, stratification according to cumulative dose did not
show a decreased bone fracture risk with increasing cumu-
lative GLP1-ra dose. We showed in a population-based co-
hort study that GLP1-ra use is not associated with a
decreased bone fracture risk compared to users of other anti-
hyperglycemic drugs. Future research is needed to elucidate
the potential working mechanisms of GLP1-ra on bone.
Keywords GLP1-ra  Fracture  Diabetes mellitus type 2 
Cohort study  CPRD
Introduction
In individuals with type 2 diabetes, the risk of bone fracture
is increased compared to individuals without type 2 dia-
betes [1]. This increased risk might be associated with the
pathobiology of type 2 diabetes itself, although the un-
derlying mechanisms remain largely unknown [2]. Alter-
natively, it has been suggested that this increased bone
fracture risk is a consequence of the kind of therapeutic
regimen initiated to combat hyperglycemia [3]. For in-
stance, thiazolidinediones [4–6] have shown to increase
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fracture risk. It has been suggested that human recombinant
insulins [7] also increase bone fracture risk, whereas met-
formin might actually decrease it [8].
Glucagon-like peptide-1 receptor agonists (GLP1-ra) are
a relative new class of anti-hyperglycemic drugs, which
may positively affect bone metabolism [9–11] and decrease
bone fracture risk. However, a recent meta-analysis, based
upon randomized clinical trial data, in which bone fractures
were not a primary outcome, did not show a decreased
bone fracture risk [12]. Thus, the aim of the present study
was to investigate, in a large population-based cohort
study, the association between GLP1-ra use and the risk of
bone fractures in individuals with type 2 diabetes.
Methods
Data Source
Data were obtained from the British Clinical Practice Re-
search Datalink [CPRD; previously the General Practice
Research Database (GPRD); see (www.CPRD.com)]. The
CPRD contains computerized medical records of 625 pri-
mary care practices in the United Kingdom (UK), and
patients represent 8 % of the UK population. Data have
been collected since 1987 and include, amongst others,
demographic information, prescription details, data on
morbidity and mortality, preventive care provided and
specialist referrals. Data in the CPRD have been shown to
be accurate and valid [13]. Particularly, with regard to the
main outcome of the present study, fractures have been
validated in over 90 % of all cases [14].
Study Population
We conducted a population-based cohort study. The
population consisted of all patients with at least one pre-
scription for a non-insulin anti-hyperglycemic drug
(NIAD) and who were aged 18? during the period of valid
CPRD data collection [15]. Cohort entry was defined as the
date of first prescription for GLP1-ra, identified between
June 13th, 2007 and August 31, 2012. The index date was
defined as the date of the first NIAD prescription; thereby
the study population was a mix of incident and prevalent
NIAD users. Patients were followed from the index date to
the end of data collection, date of transfer of the patient out
of the practice area, patient’s death, or fracture types of
interest, whichever came first.
Exposure
Follow-up time was divided into intervals based on NIAD
and insulin prescriptions. Thus a new interval was created
for every prescription. When there was a washout period of
90 days, an interval was classified as ‘‘past use’’, until end
of follow-up, or a new anti-hyperglycemic drug prescrip-
tion, whichever came first. In all other circumstances, an
interval was classified as ‘‘current use’’. If no GLP1-ra was
prescribed during follow-up, person-time was classified as
never use of GLP1-ra.
All GLP1-ra exposed intervals were classified, accord-
ing to the time since the most recent prescription, as current
(1–90 days), recent (91–180 days), or past (over 180 days)
GLP1-ra use. At every current use interval, the cumulative
prescribed GLP1-ra dosage, in exenatide dose equivalents,
was reviewed and divided by the GLP1-ra treatment time
(difference in time between the start of the first and last
GLP1-ra prescription) to estimate the average daily GLP1-
ra dose. Defined daily doses were used to calculate the
exenatide dose equivalents [16].
Outcomes
Patients were followed from the index date to the end of
data collection, date of transfer of the patient out of the
practice area, patient’s death, or fracture types of interest,
whichever came first. Fractures were classified with the use
of READ codes [17] into hip, radius and (or) ulna, verte-
bral, humerus and other fractures. A major osteoporotic
fracture was defined according to the WHO definition as a
fracture of the hip, humerus, vertebral or radius/ulna [18].
Other Variables
The presence of risk factors for bone fractures was assessed
by reviewing the computerized medical records for any
record of any risk factors for bone fractures prior to the
start of an interval. The following potential confounders
were determined at baseline: sex, body mass index (BMI),
smoking status and alcohol use. All other potential con-
founders that were considered in this study were deter-
mined time-dependent (i.e. at the start of each interval):
age, falls in 7–12 months before the start of an interval, a
history of chronic obstructive pulmonary disease (COPD),
a previous fracture, rheumatoid arthritis, hypothyroidism,
hyperthyroidism, cancer, retinopathy, neuropathy, sec-
ondary osteoporosis (hypogonadism or early menopause)
and congestive heart failure. The most recent HbA1c value
up to 1 year prior to the start of an interval was determined.
The following drug prescriptions, in the 6 months prior to
the start of an interval, were considered potential con-
founders; oral glucocorticoids [19], cholesterol lowering
drugs, antidepressants [20], anxiolytics or hypnotics [21],
antipsychotics, anti-Parkinson drugs [22], antihyperten-
sives (beta-blockers, thiazide diuretics, renin-angiotensin-
aldosterone-system (RAAS) inhibitors, calcium channel
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blockers and loop diuretics), antiarrhythmics, hormone
replacement therapy, calcium, bisphosphonates, vitamin D,
raloxifene, strontium ranelate, calcitonin and parathyroid
hormone.
Statistical Analyses
Regression analysis with Cox proportional hazards models
(SAS 9.2, PHREG procedure) was used to estimate bone
fracture risk of GLP1-ra users (current, recent or past)
compared to never-GLP1-ra users. Current GLP1-ra use
was further stratified to age and gender, and the main
analyses were repeated for major osteoporotic bone frac-
ture risk. In a series of further analyses, current GLP1-ra
use was stratified according to type of GLP1-ra (i.e. exe-
natide and liraglutide), daily and cumulative dose. As a
sensitivity analysis, the person-time for thiazolidinediones
(TZD) was excluded from the reference group and anal-
ysed as a separate group.
In all analyses, potential confounders were included if
they independently changed the beta-coefficient for current
GLP1-ra exposure by at least 5 %, or when consensus
about inclusion existed within the team of researchers,
supported by clinical evidence from the literature.
Results
Study Population and Follow-up
In total, 216,816 individuals were included in the present
study, of which 8,354 used GLP1-ra (either current, recent
or past). The characteristics of the study population are
presented in Table 1. On average, GLP1-ra users were
younger than never-GLP1-ra users (53.5 vs. 61.0 years),
and had a higher BMI (37.5 vs. 31.0). The median duration
of follow-up time (from start of follow-up to end of data
collection) was 5.1 years [Interquartile Range (IQR):
3.6–5.2 years] for GLP1-ra users and 3.6 years [IQR:
1.6–5.2 years] for never-GLP1-ra users.
Current, Recent or Past GLP1-ra Use and the Risk
of Bone Fracture
After adjusting for confounders, the risk for bone fractures
with current GLP1-ra, compared to never-GLP1-ra users,
was [Hazard Ratio (HR) and (95 %CI)] 0.99 (0.82–1.19),
with recent GLP1-ra use: 1.19 (0.66–2.14) and with past
GLP1-ra use: 1.38 (1.03–1.84), Table 2. Stratification of
current GLP1-ra by GLP1-ra type resulted in an adjusted
(adj.) HR of 0.90 (0.69–1.17) with use of liraglutide and an
adj. HR of 1.08 (0.84–1.38) with exenatide use.
When stratified by sex, bone fracture risk for current
male GLP1-ra users was 1.01 (0.76–1.33) and for current
female GLP1-ra users was 0.96 (0.75–1.22), Table 2. After
stratification by age group (i.e. 18–49, 50–59, 60–69 and
C70 years), the risk for bone fractures among patients with
current GLP1-ra use aged 18–49 was 0.80 (0.52–1.25),
aged 50–59 was 0.80 (0.56–1.15), aged 60–69 was 1.38
(1.04–1.83) and aged 70 years or older was 0.68
(0.39–1.18), Table 2.
As compared to never-GLP1-ra use, the risk for major
osteoporotic fractures with current GLP1-ra use was 0.97
(0.72–1.32); with recent GLP1-ra use, 1.13 (0.42–3.02) and
with past GLP1-ra use, 1.04 (0.61–1.76), Table 3, (detailed
data not shown). Current GLP1-ra use was not associated
with a decreased bone fracture risk for other fracture types,
Table 3.
Bone Fracture Risk and Current GLP1-ra Use
Stratified According to Dosage
If current GLP1-ra use was stratified according to cumu-
lative dose (i.e. 0–2.7 mg, 2.8–5.4 mg, 5.5–8.2 mg and
C8.3 mg exenatide dose equivalents) the results showed
that, as compared to never-GLP1-ra users, bone fracture
risk for 0–2.7 mg was 1.02 (95 % CI 0.75–1.40), for
2.7–5.5 mg, 0.89 (0.60–1.34); for 5.5–8.2 mg, 0.94
(0.58–1.52) and for C8.3 mg, 1.03 (0.75–1.41). When
stratified according to current GLP1-ra average daily dose
use (i.e. missing, 0–15 mcg, 16–20 mcg and [20 mcg
exenatide dose equivalents), the results were not substan-
tially altered, Table 4.
Sensitivity Analyses
As TZD use has been associated with an increased risk of
fracture, we additionally excluded for the main analysis all
TZD exposed person-time from the reference group and
analysed it as a separate group. This did not substantially
change the results of GLP1-ra use (adj. HR with current
GLP1-ra use; 1.03 (0.86–1.24), with recent GLP1-ra use;
1.19 (0.66–2.15) and with past GLP1-ra use; 1.38
(1.03–1.84)).
Discussion
The results of the present population-based study show that
(osteoporotic) bone fracture risk was not decreased by
GLP1-ra use. In addition, stratification according to cu-
mulative dose did not show a decreased risk of bone
fracture with increasing cumulative GLP-1 dose. The re-
sults of the present study thereby do not support the hy-
pothesis that GLP1-ra use may reduce bone fracture risk in
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Table 1 Baseline characteristics of GLP1-ra users and never-GLP1-ra users
Characteristics GLP1-ra usersa N = 8354 Never-GLP1-ra usersb N = 208,462
Median [IQR] follow-up time (years) 5.1 [3.6–5.2] 3.6 [1.6–5.2]
Median [IQR] duration of actual GLP1-ra use (years) 1.7 [0.8–2.7] n/a
Women 3904 (46.7) 98,614 (47.3)
Age
Mean age at index date, (years) (SD) 53.5 (10.5) 61.0 (15.1)
18–49 2952 (35.3) 43,574 (20.9)
50–59 2909 (34.8) 41,717 (20.0)
60–69 1986 (23.8) 54,865 (26.3)
70–79 481 (5.8) 46,907 (22.5)
80? 26 (0.3) 21,399 (10.3)
BMI
Mean BMI at index date, (SD) 37.5 (7.1) 31.0 (6.5)
\20.0 kg/m2 3 (0.0) 2759 (1.3)
20.0–24.9 kg/m2 84 (1.0) 26,969 (12.9)
25.0–29.9 kg/m2 936 (11.2) 67,550 (32.4)
30.0–34.9 kg/m2 2369 (28.4) 57,826 (27.7)
C35.0 kg/m2 4921 (58.9) 48,016 (23.0)
Missing 41 (0.5) 5342 (2.6)
HbA1c (%)
Mean (SD) 8.6 (1.9) 8.0 (1.8)
Missing 2915 (34.9) 88,937 (42.7)
Smoking status
Never 3949 (47.3) 103,970 (49.9)
Current 1945 (23.3) 41,110 (19.7)
Ex 2458 (29.4) 62,287 (29.9)
Missing 2 (0.0) 1095 (0.5)
Alcohol use
No 2417 (28.9) 60,278 (28.9)
Yes 5638 (67.5) 136,373 (65.4)
Missing 299 (3.6) 11,811 (5.7)
Falls (7–12 months before) 52 (0.6) 2141 (1.0)
History of diseases
Fracture 52 (0.6) 1342 (0.6)
Hyperthyroidism 64 (0.8) 2014 (1.0)
Hypothyroidism 719 (8.6) 16,413 (7.9)
COPD 345 (4.1) 11,585 (5.6)
Congestive heart failure 244 (2.9) 8846 (4.2)
Cancer 1626 (19.5) 45,626 (21.9)
Rheumatoid arthritis 109 (1.3) 3633 (1.7)
Retinopathy 1284 (15.4) 24,954 (12.0)
Secondary osteoporosis 895 (10.7) 18,571 (8.9)
Neuropathy 768 (9.2) 15,652 (7.5)
Drug use within 6 months before
Metformin 7367 (88.2) 171,699 (82.4)
Sulfonylurea derivatives 4589 (54.9) 54,874 (26.3)
Thiazolidinediones 2108 (25.2) 20,293 (9.7)
Insulin 2238 (26.8) 22,556 (10.8)
DPP4 inhibitors 144 (1.7) 1374 (0.7)
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individuals with type 2 diabetes. The results of our study
add to the field population-based data and are indirectly
supported by a clinical trial on the effect of exenatide on
markers of bone remodelling and calcium homeostasis,
which failed to show a positive effect [23]. Our study is
thereby in line with a recent meta-analysis [12] done on
randomized clinical trial data. Another more recent meta-
analysis also showed no association between use of GLP1-
ra and fracture risk [24]. However, after stratification to
GLP1-ra type, they found a decreased risk of fracture with
use of liraglutide and an increased risk of fracture with use
of exenatide. The results of our study did not show a de-
creased or increased risk after stratification by GLP1-ra
type. It has to be taken into account, however, that the
included studies of these meta-analyses were not designed
to investigate fracture risk and that fractures were not
routinely registered. The results of our study are also in
keeping with the results of a large cohort study on the use
of dipeptidyl peptidase-4 inhibitors (DPP4-I) and fracture
risk which also did not show a decreased fracture risk [25].
The pathways through which GLP1-ra’s may act on
bone metabolism are not fully elucidated, but it has been
suggested that GLP1-ra’s may, either directly or indirectly,
shift the balance in bone homeostasis towards bone for-
mation [26], via receptor coupling on osteoblasts [27] and
(or) thyroid C cells [28, 29]. Alternatively, it has been
suggested that GLP1-ra may increase calcitonin
concentration [29, 30] and decrease sclerostin which both
may inhibit bone formation [31]. Nevertheless, it remains
to be determined whether such mechanisms may also be
operative in humans. Interestingly, a recent meta-analysis
of clinical trial data on the use of DPP4-I did show a 40 %
reduction in the risk of bone fracture [32]. The latter brings
forward the hypothesis that any effects on bone metabolism
by DPP4-I might be independent from the direct effect of
GLP1 on bone, despite the pharmacodynamics through
which they are linked [3]. However, the underlying
mechanisms between anti-hyperglycemic drug use along
the GLP-1/DPP4-I axis and bone fracture risk in type 2
diabetes in humans remain complex.
Unexpectedly, our results showed a 1.4-fold increase in
bone fracture risk for past GLP1-ra users (GLP1-ra use had
discontinued C180 days) and for patients aged 60–69
compared to never-GLP1-ra users. As any plausible un-
derlying mechanism seems missing, we consider these re-
sults as a play of chance.
Our study had several strengths. Firstly, the results were
based upon population-based data that may have prevented,
at least partially, selection bias as compared to randomized
clinical trials in which only patients meeting specific in-
clusion criteria are able to participate. Secondly, bone
fractures are often not primary end-points in clinical trials,
thus their registration may be inadequate. The current
study, however, was able to partially circumvent this
Table 1 continued
Characteristics GLP1-ra usersa N = 8354 Never-GLP1-ra usersb N = 208,462
Glucocorticoids 439 (5.3) 12,077 (5.8)
Statins 5803 (69.5) 113,343 (54.4)
Antiarrhythmics 125 (1.5) 3336 (1.6)
Antidepressants 2075 (24.8) 32,995 (15.8)
Anti-Parkinson drugs 24 (0.3) 1040 (0.5)
Antipsychotics 157 (1.9) 4343 (2.1)
Anxiolytics 658 (7.9) 14,752 (7.1)
Hypnotics 437 (5.2) 10,242 (4.9)
Antihypertensives 5651 (67.6) 120,188 (57.7)
Bisphosphonates 87 (1.0) 5569 (2.7)
Raloxifene 5 (0.1) 298 (0.1)
Vitamin D 42 (0.5) 1161 (0.6)
Calcium 145 (1.7) 8263 (3.9)
Strontium 0 (-) 124 (0.1)
PTH/calcitonin 0 (-) 0 (-)
Hormone replacement therapy 71 (0.8) 835 (0.4)
Data are number (%) of patients, unless stated otherwise
SD indicates standard deviation, BMI body mass index, COPD chronic obstructive pulmonary disease, PTH parathyroid hormone, GLP1-ra
glucagon-like peptide-1 receptor agonist, IQR interquartile range, DPP4 dipeptidyl peptidase 4
a GLP1-ra users are patients who had at least 1 GLP1-ra prescription during follow-up
b Never-GLP1-ra users are patients who had at least 1 NIAD prescription other than GLP1-ra, during follow-up
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potential bias, as over 90 % of all fractures have been
clinically validated in the CPRD [14]. Finally, all par-
ticipants were extensively clinically characterized which
allowed us to take a series of potential confounders, in-
cluding prior medical history, into account. In addition, we
were able to adjust for neuropathy, retinopathy and HbA1c
with which we tried to capture disease severity. In par-
ticular, HbA1c could act as a potential confounder of the
association between GLP1-ra use and bone fracture risk in
individuals with type 2 diabetes. However, it is acknowl-
edged that some residual confounding may still be present.
When interpreting the results, a couple of limitations are
worth mentioning. First, an important consideration, in
light of the discussion on GLP1-ra use and bone fracture
risk, in terms of time effect, is the average duration of
GLP1-ra use. In our analysis, the median duration of actual
GLP1-ra use was 1.2 years (from first GLP1-ra prescription
until last GLP1-ra prescription), and this might be
relatively short. For bisphosphonate use, it has been shown
that bone fracture risk starts to decrease after 1–1.5 years
of use [33, 34]. Even for the highest cumulative dose group
(i.e. C8.3 mg), which could be equivalent to 1 DDD GLP1-
ra per day during at least 1.5 years, we did not show a
decrease in bone fracture risk. However, the time-window
for GLP1-ra to exert an effect on bone fracture risk is not
yet determined. Second, the risk of fracture is known to
increase with age [35], yet we identified that patients who
used GLP1-ra were slightly younger at baseline, compared
to never-GLP1-ra users. Thus, this might have masked the
protective effect of GLP1-ra on risk of bone fracture. Yet,
our age-stratified analyses did not show a protective effect
of GLP1-ra use on bone fracture risk. Third, GLP1-ra’s are
selectively prescribed to patients with an high BMI, which
might have influenced the results. High BMI has been as-
sociated with a lower risk of fracture [36], and this might
even strengthen the protective effect of GLP1-ra. However,










Never useb 8449 12.9 Reference Reference
Past use 47 16.1 1.48 (1.11–1.95)* 1.38 (1.03–1.84)*
Recent use 11 13.4 1.22 (0.69–2.14) 1.19 (0.66–2.14)
Current use 122 10.6 1.00 (0.83–1.20) 0.99 (0.82–1.19)
By GLP1-ra type
Liraglutide 57 9.5 0.91 (0.70–1.18) 0.90 (0.69–1.17)
Exenatide 65 11.8 1.09 (0.85–1.40) 1.08 (0.84–1.38)
By sexd
Men 53 8.5 1.02 (0.78–1.35) 1.01 (0.76–1.33)
Women 69 13.1 0.98 (0.77–1.25) 0.96 (0.75–1.22)
By agee
18–49 22 7.6 0.88 (0.57–1.35) 0.80 (0.52–1.25)
50–59 33 8.5 0.83 (0.58–1.19) 0.80 (0.56–1.15)
60–69 54 15.0 1.48 (1.12–1.95) 1.38 (1.04–1.83)
70? 13 11.3 0.60 (0.35–1.04) 0.68 (0.39–1.18)
Current GLP1-ra use: most recent prescription within 90 before start of an interval
Recent GLP1-ra use: most recent prescription within 91–180 before start of an interval
Past GLP1-ra use: most recent prescription over 180 days before start of an interval
All models are corrected for DPP4-I use
HR indicates hazards ratio, CI confidence interval, IR, incidence rate, GLP1-ra glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl
peptidase-4 inhibitor, BMI body mass index
* Statistically significant, (P\ 0.05)
a Past NIAD use not shown, therefore, the total number of fractures does not add up
b Never GLP1-ra use does not include use of DPP4-I
c Adjusted for sex, age, BMI, smoking status, HbA1c, retinopathy, neuropathy, secondary osteoporosis, and the use of glucocorticoids,
cholesterol lowering drugs, hypnotic/anxiolytic drugs and antidepressants
d Models not statistically adjusted for sex
e Models not statistically adjusted for age
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Table 3 Risk of bone fracture in current GLP1-ra users stratified to fracture type









Never-GLP1-ra usea 4373 6.1 Reference Reference
Current GLP1-ra use 44 3.7 0.97 (0.71–1.31) 0.97 (0.72–1.32)b
Hip fracture
Never-GLP1-ra usea 1383 1.9 Reference Reference
Current GLP1-ra use 2 0.2 0.26 (0.06–1.03) 0.27 (0.07–1.08)c
Radius/ulna fracture
Never-GLP1-ra usea 1442 2.0 Reference Reference
Current GLP1-ra use 15 1.3 1.78 (0.47–1.32) 0.82 (0.48–1.37)d
Vertebral fracture
Never-GLP1-ra usea 513 0.7 Reference Reference
Current GLP1-ra use 8 0.7 1.59 (0.78–3.24) 1.64 (0.80–3.37)e
Current GLP1-ra use: most recent prescription within 90 before start of an interval
All models are corrected for DPP4-I use
HR indicates hazards ratio, CI confidence interval, IR incidence rate, GLP1-ra glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl
peptidase-4 inhibitor, BMI body mass index
* Statistically significant, (P\ 0.05)
a Never-GLP1-ra use does not include use of DPP4-I
b Adjusted for (f), and history of congestive heart failure, use of cholesterol lowering drugs, antidepressants, hypnotics/anxiolytics, calcium and
anti-osteoporotic drugsg
c Adjusted for (f), and the use of glucocorticoids, antidepressants, and falls 7–12 months before index date
d Adjusted for (f), and the use of cholesterol lowering drugs, antidepressants, hypnotics/anxiolytics, anti-osteoporotic drugsg and glucocorticoids
e Adjusted for (f), and history of congestive heart failure, use of cholesterol lowering drugs, antidepressants, hypnotics/anxiolytics and
glucocorticoids
f Sex, age, BMI, smoking status, HbA1c, retinopathy, neuropathy and secondary osteoporosis
g Use of bisphosphonates, raloxifene, strontium ranelate or PTH/calcitonin
Table 4 Risk of bone fracture in current GLP1-ra users compared to never-GLP1-ra users, stratified by average and cumulative DDD exposure
No. of fractures Fracture IR (/1000 PY) Age/sex adjusted HR (95 % CI) Adjusted HR (95 % CI)b
Never-GLP1-ra usea 8449 12.9 Reference Reference
Current GLP1-ra use
By average DDD exposure (in exenatide equivalents)
0–15 mcg 48 16.9 1.05 (0.79–1.40) 1.03 (0.78–1.38)
16–20 mcg 37 8.7 0.82 (0.59–1.14) 0.82 (0.59–1.13)
C21 mcg 28 14.3 1.29 (0.89–1.88) 1.27 (0.88–1.85)
No dose 9 9.8 0.91 (0.48–1.76) 0.90 (0.47–1.73)
By cumulative DDD exposure (in exenatide equivalents)
0–2.7 mg 41 11.3 1.03 (0.76–1.41) 1.02 (0.75–1.40)
2.8–5.4 mg 24 9.4 0.90 (0.60–1.35) 0.89 (0.60–1.34)
5.5–8.2 mg 17 9.9 0.95 (0.59–1.53) 0.94 (0.58–1.52)
C8.3 mg 40 11.0 1.05 (0.77–1.44) 1.03 (0.75–1.41)
All models are corrected for DPP4-I use
HR hazards ratio, CI confidence interval, IR incidence rate, GLP1-ra glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl peptidase-4
inhibitor
a NIAD past use, GLP1-ra recent and GLP1-ra past use not shown. Never-GLP1-ra use does not include use of DPP4-I
b Adjusted for sex, age, bmi, smoking status, HbA1c, history of secondary osteoporosis, retinopathy and neuropathy, use of glucocorticoids,
cholesterol lowering drugs, hypnotic/anxiolytic drugs and antidepressants
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we could not show a protective effect of GLP1-ra on
fracture risk. Fourth, after stratification of the analyses to
specific fracture types, the number of fractures within the
current GLP1-ra group became low, and therefore, the re-
sults should be interpreted with caution.
In summary, we showed in a population-based cohort
study that GLP1-ra use is not associated with a decreased
risk of bone fracture as compared to users of other anti-
hyperglycemic drugs. Future research is needed to eluci-
date the working mechanisms of the complex GLP-1/DPP-
4 axis and to investigate the time-window of GLP1-ra to
exert an effect on bone fracture risk.
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